Genocea Biosciences Inc. sell StockNews.com
Summary
This prediction was cancelled by the user.Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - |
| iShares Core DAX® | -1.875% | 2.861% | 18.863% |
| iShares Nasdaq 100 | -2.177% | 0.048% | 3.956% |
| iShares Nikkei 225® | -0.867% | 6.987% | 21.062% |
| iShares S&P 500 | -1.253% | 1.248% | 2.246% |
Comments by StockNews_com for this prediction
In the thread Genocea Biosciences Inc. diskutieren
In the thread Trading Genocea Biosciences Inc.